Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHSJad Othman, Richard Dillon, I. Ben Abdallah et al.|Blood Neoplasia|2024Cited by 36
Outcomes with single-agent gilteritinib for relapsed or refractory <i>FLT3</i>-mutant AML after contemporary induction therapyJad Othman, Richard Dillon, Angela Hwang et al.|Blood Advances|2024Cited by 10